Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Agouron's IND for anticancer agent approved

June 20, 1997

Sugen receives notices of allowance covering SU-101 for solid tumor treatment

June 19, 1997

NeoPharm begins phase I/II trial for liposome-encapsulated doxorubicin

June 18, 1997

Results from phase II trial with thalidomide for prostate cancer reported

June 18, 1997

Suntory prepares compounds for thrombocytopenia

June 17, 1997

Merck & Co. prepares improved inhibitors of protein farnesyltransferase

June 17, 1997

U.S. notice of patent allowance for troponin I

June 16, 1997

Banyu to shift development from NB-506 to new indolocarbazole

June 13, 1997

Paracelsian cancels launch of AndroCar

June 12, 1997

Milkhaus initiates phase II trial for prostate cancer

June 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...